FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R]
- Citation:
- Blood vol 112 (11) abstr 1003
- Meeting Instance:
- ASH 2008
- Year:
- 2008
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 976
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- M. S. Czuczman J. P. Leonard J. L. Johnson S.-H. Jung E. Hsi J. C. Byrd B. D. Cheson
- Networks:
- Study
- CALGB-50402
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: